PerkinElmer, Inc. ( PKI Quick Quote PKI - Free Report) recently introduced the GC 2400 Platform that can help lab teams to streamline lab operations, deliver precise results and perform more flexible monitoring. The GC 2400 Platform is an advanced, automated gas chromatography (GC), headspace sampler and GC/mass spectrometry (GC/MS) solution and has been created for high throughput environments. The new platform has been designed to be productive with respect to pharmaceutical, food, environmental and industrial analyses. In fact, this platform combines systems, software and a broad range of columns and consumables to cater to customers’ different workflow needs. The launch of this platform is likely to boost PerkinElmer’s Environment Health business line – part of the company’s Discovery & Analytical Solutions (DAS) segment. Benefits of the GC 2400 Platform
When it comes to complicated applications and high throughput lab environments, the GC automated sampling capabilities help to lower hands-on time and human error, while the industry-unique automated headspace/pneumatics technology provides superior precision.
Image Source: Zacks Investment Research
Whether inside or outside the lab, monitoring single or multiple GC 2400 systems is easy through the utilization of the wireless, touchscreen tablet interface running the PerkinElmer Simplicity Vision app.
By taking into account sustainability and safety, built-in sensors and a software-driven gas saver mode lower operational gas consumption and lend support to carrier gas alternatives such as hydrogen. Per management, this platform enables teams of any experience level to better manage and monitor their GC analyses from the sample through result, which can help them focus on high-value activities in their labs and businesses. Market Prospects
a report by Grand View Research, the global gas chromatography market was worth $2.5 billion in 2016 and is anticipated to witness a CAGR of 6.4% during the forecast period (2018-2025). The rising adoption of GC in different industries and technological advancements in GC is likely to drive market growth. Hence, this announcement comes at an opportune time for PerkinElmer. Recent Developments
This month, PerkinElmer’s company – EUROIMMUN – introduced two CE-marked assays that allow the identification of IgG antibodies that form against SARS-CoV-2 and are available to laboratories in countries accepting the CE mark. The two assays are the Anti-SARS-CoV-2 RBD ChLIA (IgG) and the Anti-SARS-CoV-2 Omicron ELISA (IgG).
Again, this month, the company introduced the research use only (RUO) BioQule NGS System, which is an automated benchtop solution for next-generation sequencing (NGS) library preparation of up to eight samples. Backed by automated thermocycling, integrated quality control through optical quantification and strong liquid handling technology into a single device, the BioQule NGS System can help researchers deliver superior quality NGS libraries. Price Performance
Shares of the Zacks Rank #3 (Hold) company have lost 12.3% in a year’s time compared with the
industry’s decline of 17.2%. Stocks to Consider
Some better-ranked stocks in the broader medical space are
AMN Healthcare Services, Inc. ( AMN Quick Quote AMN - Free Report) , Masimo Corporation ( MASI Quick Quote MASI - Free Report) and ShockWave Medical, Inc. ( SWAV Quick Quote SWAV - Free Report) . AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 15.6%. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. AMN Healthcare’s long-term earnings growth rate is estimated at 1.1%. The company’s earnings yield of 11.4% compares favorably with the industry’s (0.8%). Masimo beat earnings estimates in each of the trailing four quarters, the average surprise being 4.4%. The company currently carries a Zacks Rank #2 (Buy). Masimo’s estimated earnings growth rate for second-quarter 2022 is pegged at 22.3%. The company’s earnings yield is 3.8% against the industry’s (8.5%). ShockWave Medical surpassed earnings estimates in each of the trailing four quarters, the average surprise being 189.9%. The company currently sports a Zacks Rank #1. ShockWave Medical’s earnings growth rate for 2022 is estimated at 807.7%. The company’s earnings yield of 0.9% compares favorably with the industry’s (8%).